DOI QR코드

DOI QR Code

Identification of Serum MicroRNA-21 as a Biomarker for Early Detection and Prognosis in Human Epithelial Ovarian Cancer

  • Xu, Yun-Zhao (Department of Obstetrics and Gynecology, Affiliated Hospital of Nan Tong University) ;
  • Xi, Qing-Hua (Department of Obstetrics and Gynecology, Affiliated Hospital of Nan Tong University) ;
  • Ge, Wen-Liang (Department of Pediatric Surgery, Affiliated Hospital of Nan Tong University) ;
  • Zhang, Xiao-Qian (Department of Obstetrics and Gynecology, Affiliated Hospital of Nan Tong University)
  • 발행 : 2013.02.28

초록

Recent investigations have confirmed up-regulation of serum miR-21 and its diagnostic and prognostic value in several human malignancies. In this study, we examined serum miR-21 levels in epithelial ovarian cancer (EOC) patients, and explored its association with clinicopathological factors and prognosis. The results showed significantly higher serum miR-21 levels in EOC patients than in healthy controls. In addition, increased serum miR-21 expression was correlated with advanced FIGO stage, high tumor grade, and shortened overall survival. These findings indicate that serum miR-21 may serve as a novel diagnostic and prognostic marker, and be used as a therapeutic target for the treatment of EOC.

키워드

참고문헌

  1. Asaga S, Kuo C, Nguyen T, et al (2011). Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem, 57, 84-91. https://doi.org/10.1373/clinchem.2010.151845
  2. Bartel DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-97. https://doi.org/10.1016/S0092-8674(04)00045-5
  3. Brennecke J, Stark A, Russell RB, Cohen SM (2005). Principles of microRNA-target recognition. PLoS Biol, 3, e85. https://doi.org/10.1371/journal.pbio.0030085
  4. Calin GA, Sevignani C, Dumitru CD, et al (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A, 101, 2999-3004. https://doi.org/10.1073/pnas.0307323101
  5. Chan JA, Krichevsky AM, Kosik KS (2005). MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res, 65, 6029-33. https://doi.org/10.1158/0008-5472.CAN-05-0137
  6. Chan SH, Wu CW, Li AF, et al (2008). miR-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Res, 28, 907-11.
  7. Corney DC, Hwang CI, Matoso A, et al (2010). Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res, 16, 1119-28. https://doi.org/10.1158/1078-0432.CCR-09-2642
  8. Davidson-Moncada J, Papavasiliou FN, Tam W (2010). MicroRNAs of the immune system: roles in inflammation and cancer. Ann N Y Acad Sci, 1183, 183-94. https://doi.org/10.1111/j.1749-6632.2009.05121.x
  9. Feber A, Xi L, Luketich JD, et al (2008). MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg, 135, 255-60; discussion 60. https://doi.org/10.1016/j.jtcvs.2007.08.055
  10. Friedman RC, Farh KK, Burge CB, Bartel DP (2009). Most mammalian mRNAs are conserved targets of microRNAs. Genome Res, 19, 92-105.
  11. Hiyoshi Y, Kamohara H, Karashima R, et al (2009). MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res, 15, 1915-22. https://doi.org/10.1158/1078-0432.CCR-08-2545
  12. Iorio MV, Ferracin M, Liu CG, et al (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 65, 7065-70. https://doi.org/10.1158/0008-5472.CAN-05-1783
  13. Iorio MV, Visone R, Di Leva G, et al (2007). MicroRNA signatures in human ovarian cancer. Cancer Res, 67, 8699-707. https://doi.org/10.1158/0008-5472.CAN-07-1936
  14. Krek A, Grun D, Poy MN, et al (2005). Combinatorial microRNA target predictions. Nat Genet, 37, 495-500. https://doi.org/10.1038/ng1536
  15. Kuehbacher A, Urbich C, and Dimmeler S (2008). Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol Sci, 29, 12-5. https://doi.org/10.1016/j.tips.2007.10.014
  16. Kurashige J, Kamohara H, Watanabe M, et al (2012). Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. J Surg Oncol, 106, 188-92. https://doi.org/10.1002/jso.23064
  17. Lawrie CH, Gal S, Dunlop HM, et al (2008). Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol, 141, 672-5. https://doi.org/10.1111/j.1365-2141.2008.07077.x
  18. Liu ZY, Zhang GL, Wang MM, et al (2011). MicroRNA-663 targets TGFB1 and regulates lung cancer proliferation. Asian Pac J Cancer Prev,12, 2819-23.
  19. Malpica A, Deavers MT, Lu K, et al (2004). Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol, 28, 496-504. https://doi.org/10.1097/00000478-200404000-00009
  20. Markou A, Tsaroucha EG, Kaklamanis L, et al (2008). Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem, 54, 1696-704. https://doi.org/10.1373/clinchem.2007.101741
  21. Meng F, Henson R, Lang M, et al (2006). Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology, 130, 2113-29. https://doi.org/10.1053/j.gastro.2006.02.057
  22. Meng F, Henson R, Wehbe-Janek H, et al (2007). MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 133, 647-58. https://doi.org/10.1053/j.gastro.2007.05.022
  23. Roldo C, Missiaglia E, Hagan JP, et al (2006). MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol, 24, 4677-84. https://doi.org/10.1200/JCO.2005.05.5194
  24. Sabatel C, Malvaux L, Bovy N, et al (2011). MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. PLoS One, 6, e16979. https://doi.org/10.1371/journal.pone.0016979
  25. Si ML, Zhu S, Wu H, et al (2007). miR-21-mediated tumor growth. Oncogene, 26, 2799-803. https://doi.org/10.1038/sj.onc.1210083
  26. Slaby O, Svoboda M, Fabian P, et al (2007). Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology(Williston Park), 72, 397-402.
  27. Song T, Xia W, Shao N, et al (2010). Differential miRNA expression profiles in bladder urothelial carcinomas. Asian Pac J Cancer Prev, 11, 905-11.
  28. Tran N, McLean T, Zhang X, et al (2007). MicroRNA expression profiles in head and neck cancer cell lines. Biochem Biophys Res Commun, 358, 12-7. https://doi.org/10.1016/j.bbrc.2007.03.201
  29. Tsujiura M, Ichikawa D, Komatsu S, et al (2010). Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer, 102, 1174-9. https://doi.org/10.1038/sj.bjc.6605608
  30. Volinia S, Calin GA, Liu CG, et al (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A, 103, 2257-61. https://doi.org/10.1073/pnas.0510565103
  31. Wang P, Zhuang L, Zhang J, et al (2012). The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL. Mol Oncol, pii: S1574-7891(12)00109-3.
  32. Wang ZX, Bian HB, Wang JR, et al (2011). Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. J Surg Oncol,104, 847-51. https://doi.org/10.1002/jso.22008
  33. Xu J, Wu C, Che X, et al (2011). Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog, 50, 136-42. https://doi.org/10.1002/mc.20712
  34. Yang H, Kong W, He L, et al (2008). MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res, 68, 425-33. https://doi.org/10.1158/0008-5472.CAN-07-2488
  35. Zhang B, Cai FF, Zhong XY (2011a). An overview of biomarkers for the ovarian cancer diagnosis. Eur J Obstet Gynecol Reprod Biol, 158, 119-23. https://doi.org/10.1016/j.ejogrb.2011.04.023
  36. Zhang HL, Yang LF, Zhu Y, et al (2011b). Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate, 71, 326-31. https://doi.org/10.1002/pros.21246
  37. Zhang Z, Li Z, Gao C, et al (2008). miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest, 88, 1358-66. https://doi.org/10.1038/labinvest.2008.94
  38. Zhou L, Zhao YP, Liu WJ, et al (2012). Circulating microRNAs in cancer: diagnostic and prognostic significance. Expert Rev Anticancer Ther,12, 283-8. https://doi.org/10.1586/era.11.197

피인용 문헌

  1. Clinical relevance of circulating cell-free microRNAs in cancer vol.11, pp.3, 2014, https://doi.org/10.1038/nrclinonc.2014.5
  2. Detection of MicroRNA-21 Expression as a Potential Screening Biomarker for Colorectal Cancer: a Meta-analysis vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7583
  3. Differential microRNA Expression by Solexa Sequencing in the Sera of Ovarian Cancer Patients vol.15, pp.4, 2014, https://doi.org/10.7314/APJCP.2014.15.4.1739
  4. miR-21 increases the programmed cell death 4 gene-regulated cell proliferation in head and neck squamous carcinoma cell lines vol.32, pp.5, 2014, https://doi.org/10.3892/or.2014.3456
  5. Prognostic role of circulating microRNA-21 in cancers: evidence from a meta-analysis vol.35, pp.7, 2014, https://doi.org/10.1007/s13277-014-1846-8
  6. Role of microRNAs in malignant mesothelioma vol.71, pp.15, 2014, https://doi.org/10.1007/s00018-014-1584-5
  7. microRNA-206 overexpression inhibits cellular proliferation and invasion of estrogen receptor α-positive ovarian cancer cells vol.9, pp.5, 2014, https://doi.org/10.3892/mmr.2014.2021
  8. MicroRNA-21 Identified as Predictor of Cancer Outcome: A Meta-Analysis vol.9, pp.8, 2014, https://doi.org/10.1371/journal.pone.0103373
  9. Activities of E6 Protein of Human Papillomavirus 16 Asian Variant on miR-21 Up-regulation and Expression of Human Immune Response Genes vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3961
  10. miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy vol.47, pp.5, 2015, https://doi.org/10.1038/emm.2015.17
  11. Current status on microRNAs as biomarkers for ovarian cancer vol.124, pp.5, 2016, https://doi.org/10.1111/apm.12514
  12. Clinical relevance of circulating cell-free microRNAs in ovarian cancer vol.15, pp.1, 2016, https://doi.org/10.1186/s12943-016-0536-0
  13. MicroRNA and Long Non-Coding RNA in Ovarian Carcinoma: Translational Insights and Potential Clinical Applications vol.34, pp.9, 2016, https://doi.org/10.1080/07357907.2016.1227446
  14. Human epididymis protein 4 expression positively correlated with miR-21 and served as a prognostic indicator in ovarian cancer vol.37, pp.6, 2016, https://doi.org/10.1007/s13277-015-4672-8
  15. Updates and current challenges in microRNA research for personalized medicine in ovarian cancer vol.17, pp.8, 2017, https://doi.org/10.1080/14712598.2017.1340935
  16. The Diagnostic and Prognostic Potential of microRNAs in Epithelial Ovarian Carcinoma vol.21, pp.1, 2017, https://doi.org/10.1007/s40291-016-0242-z
  17. Differential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancer vol.8, pp.2, 2014, https://doi.org/10.3892/ol.2014.2214
  18. Tumor-Associated CSF MicroRNAs for the Prediction and Evaluation of CNS Malignancies vol.16, pp.12, 2015, https://doi.org/10.3390/ijms161226150
  19. Circulating MicroRNAs as Biomarkers and Mediators of Cell–Cell Communication in Cancer vol.3, pp.4, 2015, https://doi.org/10.3390/biomedicines3040270
  20. miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer vol.9, pp.3, 2015, https://doi.org/10.2217/bmm.14.108
  21. New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies vol.17, pp.5, 2016, https://doi.org/10.3390/ijms17050627
  22. Overexpression of Rab27B is correlated with distant metastasis and poor prognosis in ovarian cancer vol.12, pp.2, 2016, https://doi.org/10.3892/ol.2016.4801
  23. Role of Nerve Growth Factor (NGF) and miRNAs in Epithelial Ovarian Cancer vol.18, pp.3, 2017, https://doi.org/10.3390/ijms18030507
  24. The role of microRNAs and nanoparticles in ovarian cancer: a review pp.2169-141X, 2018, https://doi.org/10.1080/21691401.2018.1454931
  25. Circulating miR-26a and miR-21 as biomarkers for glioblastoma multiform pp.08854513, 2019, https://doi.org/10.1002/bab.1707
  26. Identification of LEA, a podocalyxin-like glycoprotein, as a predictor for the progression of colorectal cancer vol.7, pp.10, 2018, https://doi.org/10.1002/cam4.1765
  27. Micro-Raman Spectroscopy for Monitoring of Deposition Quality of High-k Stack Protective Layer onto Nanowire FET Chips for Highly Sensitive miRNA Detection vol.8, pp.3, 2018, https://doi.org/10.3390/bios8030072